The operator of an Oregon-based diagnostic testing group admits to overbilling federal and private insurers for sleep studies, resulting in an estimated loss of over $2.1 million.

The update translates recent evidence and expert consensus into practical guidance for managing restless legs syndrome.

Summary The Huxley Home Sleep Apnea Test (SANSA) prescription home sleep-related breathing disorder test indicated for adults 22 years age and older. The wearable device is a single point of contact chest-worn patch whic...

Summary The water bottle has two different Myo-Nozzle levels (1 + 2) representing different resistances to flow. Level 1 is meant for children and beginners; level 2 is for adults. Evidence to support the efficacy is lim...

The proposed rule would move suvorexant, lemborexant, and daridorexant from Schedule IV to the less restrictive Schedule V under the Controlled Substances Act.

The pharmaceutical company shared updates on its triple agonist retatrutide for obstructive sleep apnea and its acquisition of Centessa Pharmaceuticals.

Beginning in 2027, unattended sleep studies will be described as low-, moderate-, or high-complexity, based on the channels acquired and parameters reviewed—not on the device used.

An independent research institute evaluated the clinical effectiveness and value of oveporexton, an investigational orexin receptor 2 agonist for narcolepsy type 1.

In a single-site study, it reduced Insomnia Severity Index scores by an average of 65%, with all participants seeing symptom improvement.

There is a dramatic change in FDA adverse event reporting for mandibular advancement devices for obstructive sleep apnea in 2024 and 2025. Is it better reporting, a safety flag, or something else?